Urate-lowering therapy
Treatment approaches and adherence to urate-lowering therapy for patients with gout
... of urate crystals in and around the ...long-term therapy is to lower the serum urate level to promote dissolution of urate crystals, reduce recurrent acute gout flares, resolve tophi and ...
6
Gout prevalence and predictors of urate lowering therapy use: results from a population based study
... first-line urate- lowering therapy for chronic gout management in most international guidelines [12, 13], and in 2005 it accounted for more than 98% of prescriptions for ULT in Australia ...
10
Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort
... Almost a quarter of the patients in the study sample had their diuretics discontinued during follow up. Although this treatment strategy is in line with recommen- dations from the European League Against Rheumatism ...
6
Prescription and dosing of urate lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
... Results: Of the 273 patients enrolled into the study, 89 (32.6%) had SU concentration <0.36 mmol/L. Urate- lowering therapy (ULT) use was strongly associated with SU target (p < 0.001). In ...
5
Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy
... Current clinical guidelines and management pathways endorsed by the European League against Rheumatism [36], American College of Rheumatology [37] and British Society for Rheumatology [38] agree on the importance of ...
10
Baseline urate level and renal function predict outcomes of urate lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort
... monosodium urate crystals in joints and the consequent inflammation or erosion around the vic- tim joints ...of urate-lowering therapy (ULT) are 360 μmol/L (6 mg/L) in moderate gout and 300 ...
9
A joint effort over a period of time: factors affecting use of urate lowering therapy for long term treatment of gout
... encourage urate-lowering therapy (ULT) for patients with two or more acute attacks per year, tophi, renal stones, radiological damage or impaired renal ...
8
Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate lowering therapy
... during urate- lowering ...in urate deposits from baseline (G), where deposits are seen as a small tophus (large arrows), to 3 months’ follow- up (H), where deposits are reduced to aggregates (small ...
9
Factors associated with initiation and persistence of urate lowering therapy
... Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. It is also one of the few curable forms of arthritis. Gout is associated with higher age, ...
8
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
... In the primary search, citations were compiled from the following electronic databases: Ovid MEDLINE (1966- June 2013), Ovid EMBASE (1980-June 2013), CENTRAL (June 2013) and Web of Science (June 2013) using search ...
9
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population based cohort study
... Whilst it is not possible to make causal inferences from this observational study, it is worth considering the poten- tially plausible mechanisms for the association between gout and CKD. Renal damage could result from ...
10
Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy.
... For each individual in our study, we extracted information on relevant life-style related characteristics (smoking status and alcohol consumption), body mass index (BMI) and comorbidities (defined using Charlson ...
17
Facilitators and barriers to adherence to urate lowering therapy in African Americans with gout: a qualitative study
... Patients were eligible for the study if they had had one or more outpatient visit with an International Classification of Diseases, ninth revision, common modification (ICD-9- CM) code for gout, that is, 274.xx, between ...
13
Patient considerations in the management of gout and role of combination treatment with lesinurad
... of urate-lowering ...of urate-lowering therapy to prevent recurrence of acute gouty arthritis and to resolve tophi, if ...combination therapy with a uricosuric agent such as ...
8
Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial
... of urate-lowering therapy increased from 39% to 56% in the usual-care group, but allopurinol doses remained low and mean serum urate con centrations did not ...sodium urate crystals and ...
11
Tophus resolution in patients with chronic refractory gout who have persistent urate lowering responses to pegloticase
... modest lowering of the serum urate can reduce tophus burden in patients with gout, but it is difficult to directly compare results from those clinical trials with those from the present ...serum ...
10
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial
... ACR: American College of Rheumatology; AE: Adverse event; AHS: Allopurinol hypersensitivity syndrome; ALP: Alkaline phosphatase; ALT: Alanine transaminase; ANOVA: Analysis of variance; AST: Aspartate aminotransferase; ...
9
Long term persistence and adherence on urate lowering treatment can be maintained in primary care 5 year follow up of a proof of concept study
... 15. Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with ...
17
Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
... Significant IOP reductions from baseline were observed in patients previously receiving monotherapy with β -blockers (–4.6 mmHg) or with the prostaglandin analogs latano- prost ( − 2.8 mmHg), travoprost (–3.1 mmHg), ...
8
Statins: Newer Roles Including Lipid Lowering Therapy
... lipid- lowering therapy was associated with significant reduction in both cardiac mortality and all-cause death in larger cohort of patients treated with antiarrhythmic drug ...statin therapy in ...
10